◆ 会议时间：2023年10月3日至7日
◆ 会议地点：美国 波特兰

◆ 会议简介：

2023年美国妇科泌尿学会(AUGS)盆底疾病周(PFD WEEK 2023)将于2023年10月3日至7日在美国俄勒冈州波特兰举行。盆底疾病周(PFD WEEK)是AUGS年度科学会议的扩展，由AUGS于2015年创建，旨在成为对女性盆腔医学和重建外科感兴趣的相关卫生保健专业人士的首选会议，会议的核心内容包括传统的两天半的科学报告，外加一天的外科和临床研讨会。

美国妇科泌尿学会(AUGS)成立于1979年，是首屈一指的代表治疗女性盆底疾病的专业人士的非营利组织，现拥有超过1900名成员，包括执业医师，护理师，物理治疗师，护士和卫生保健专业人员以及来自其他学科的研究人员等。作为女性盆腔医学和重建外科的领导者，AUGS致力于通过卓越的教育、研究和宣宣传提升对患者的护理水平。AUGS是女性盆腔医学和重建外科（FPMRS）临床和科学信息及教育的主要来源。未经许可禁止复制摘录转载本站任何内容-国际医学会议网（lingyuint.com）.

PFD Week 2023 - AUGS Pelvic Floor Disorders (PFD) Week
Date: October 3-7, 2023
Venue: Portland, Oregon, USA

Organized by：American Urogynecologic Society (AUGS)

About PFD Week

2015 marked the debut of Pelvic Floor Disorders (PFD) Week, an expansion of the very successful AUGS Annual Scientific Meeting. PFD Week was created by AUGS to become the go-to meeting for health care professionals interested in or actively practicing Female Pelvic Medicine and Reconstructive Surgery. The core of the meeting contains the traditional two and half days of scientific presentation with the addition of one day of surgical and clinical workshop sessions.

With this expanded focus, the meeting brings together physicians, physicians-in-training, researchers, physical therapists, advance nurse practitioners, physician assistants and nurse practitioners to collaborate, network and learn from each other’s expertise. PFD Week creates the forum to learn from each other’s knowledge, experience and expertise, for the improvement of women’s urogynecologic care.

PFD Week is an inclusive meeting that offers access to internationally recognized leaders in the field and the opportunity to network with the most highly respected health professionals in Female Pelvic Medicine and Reconstructive Surgery.

摘要征文投稿：

• • February 23, 2023 - Workshop and Roundtable submission deadline
  • April 13, 2023 - Abstract submission deadline
  • Week of March 20, 2023 - Notification of invited roundtables to be sent out
  • Week of April 14, 2023 - Notification of invited workshops to be sent out
  • Week of June 12, 2023 - Notification of invited abstract to be sent out
  • June 30, 2023 – Acceptances due for invited abstracts
  • August 7, 2023 – Late-breaking science submissions open
  • August 17, 2023 - Late-breaking science submission deadline
  • Week of September 4, 2023 – Late-breaking science notifications to be sent out
  • September 8, 2023 - Oral presentation slides due

点此提交摘要>>>Submit Abstract>>>

AUGS members and non-members of any professional background or level are eligible to submit an abstract.
Abstracts presented at a professional conference outside of the U.S. are eligible and may be accepted.

Submission Guidelines

CHARACTER LIMIT
• Title character limit: No more than 95 characters.
• Body character limit: There is a combined limit of 450 words which includes Objective, Methods, Results, and Conclusions. You will be advised of your word count usage throughout the submission process as you save and move to the next step. This count does not include title, authors or affiliations.
• Figures and Tables Limit: You may add a total of two figures and/or tables. Figures and tables cannot be placed within the text of the submission. Figures and tables cannot be in color. Figures and tables will appear at the end of your abstract, both on the proof and for publication.

All abstracts should be submitted in English. Omit ALL person, group and institutional names and geographical references in the body of the abstract. Abstracts that do not adhere to this and unblind themselves within the body of the abstract are subject to downgrading.

VIDEO ABSTRACT
Videos that address topics such as surgical tips, anatomy, or educational topics are encouraged. Please ensure that your videos protect patient anonymity and integrity. The time limit for a video is 10 minutes. Video abstract submission should contain a brief description of the Objectives, Methods and Clinical Relevance of the video submission with a maximum word count of 450 words (same as abstract).

The below criteria must be met for acceptance of video presentation.
• Maximum duration: 10 minutes
• File cannot be above 2.0 GB
• Videos must have English captions or narration
• Avoid any background music that is too loud or distracting
• Please ensure that your videos protect patient anonymity and integrity.
• Acceptable file formats are .mp3, .avi, .mov, .mpg, mp4 and .m4

Please remove all product logos/names from your video. If a video is submitted with the product name/logo included, the video will be disqualified from consideration.

LATE-BREAKING SCIENCE
Late-breaking science submissions are intended to allow for the timely presentation of high impact trials to PFD Week 2023 attendees. It is expected that these abstract submissions are from studies for which no preliminary data were available at the time of the abstract submission deadline. Submissions that do not meet these criteria will be declined. Late-breaking submissions, upon acceptance, will be invited to be presented at the podium but will not be published in the program book or Urogynecology.

Priority will be given (in the following order) to:
• Results of phase III clinical trials
• Results of phase II clinical trials
• Extraordinary findings from a basic science investigation
• Interim analyses of phase III trials that describe important secondary end points
• Prospective multi-institution clinical trials

Late-breaking submissions, upon acceptance, will be invited to be presented at the podium but will not be published in the program book or Urogynecology.

We reserve the option not to accept any late-breaking science abstracts if the above criteria are not satisfied by any submissions.

Preparing for Submission

TITLE
• Please make sure you double-check your title, as it will be published as submitted.
• Use mixed case for title – do not use all caps or all lowercase. Do not put your title in quotation marks.
• Titles are limited to 2 lines and no more than 95 characters.
• Do not include trial group name in title of abstract.

AUTHORS
• Please consult with your co-authors on how they would like their names to appear. Please enter all authors in the order they should appear in the heading of the abstract. Submitting author is automatically considered the Presenter on a submission.
• All authors and co-authors must disclose any relevant financial relationship(s) at the time of submission.

Responsibilities of the Presenting Author
The first author listed for each abstract serve as the presenting author and as the primary contact for all correspondence regarding the abstract.
The presenting author is responsible for the following:
• Ensuring that all authors have read the abstract and agreed to be co-authors.
• Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by AUGS.

PRESENTER SUBSTITUTIONS
The primary author submitting the abstract must be the presenter and be involved in the research. All oral presentations are expected to be presented onsite in Portland. Presenter substitutions will only be allowed for significant changes in life circumstances or acute illness and require request and approval. Switching to a virtual presentation will not be possible.

ABSTRACT BODY
Omit all names and geographical references in the body of the abstract. Organize content in sections as follows:
• Objective: describes the research objective
• Methods: describes research methodology used
• Results: summarizes evaluation, including outcome data
• Conclusions: states the conclusions drawn from results

PRODUCT NAME USAGE
• For purposes of blind scoring, institutional names must be omitted whenever possible in the title and body of the abstract.
• Avoid the use of commercially branded names. Use scientific or generic names when referring to products
• If a specific device is only identifiable by its trade name, then this should appear in brackets after a generic description of the device.
• Should it be necessary to use a trade name, then the trade names of all similar products or those within a class must be used.

PROOFREAD YOUR ABSTRACT
• Carefully proofread your abstract. Make sure all special characters and formatting are displaying properly in your proof.
• You may return to the online submission site to revise your abstract until April 13, 2023 at 11:59 PM, ET.
• When making edits to a submitted abstract, you must save and re-submit by clicking the "continue" button.
• After this date/time, the submission site will close, and no additional changes/edits can be made.
• If you have not completed all required sections, including financial disclosures for all co-authors, you will not be able to complete your submission.

After Submission

ABSTRACT REVIEW
• After the submission site closes, completed abstracts will be peer reviewed.
• All abstracts will be blinded for reviewed without knowledge of the author/s, institution/s or disclosure information.
• Accepted abstracts will be selected as oral, short oral, scientific salon, or poster.

ABSTRACT ACCEPTANCE/REJECTION NOTIFICATIONS
• You will be notified electronically of the acceptance of your abstract during the week of June 12, 2023.
• This notification will include the date and time of your session as well as the type of presentation.
• Only the presenting author will be notified. It is the responsibility of the presenting author to notify all co-authors.

FULL PAPERS
Abstracts selected for oral presentation require the completion of a full scientific paper. This manuscript will be submitted to the program committee for use of determining abstract awards and session moderation. It will not be automatically submitted to a journal for publication but is highly encouraged.

WITHDRAWALS
• Presenting authors may withdraw an abstract submission at any time. To withdraw a submission, log into the abstract submission site, click on the title of the abstract and update the status to “withdraw”.
• In order for an accepted abstract to be withdrawn and not appear in publication, notification must be received by July 31, 2023.
• After July 31, 2023, withdrawals are still accepted but abstracts may still appear in annual meeting materials.

◆ 参会对象：医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。